Type 1 Diabetes

In this episode of Diabetes Dialogue, ours hosts discuss the clearance of Tidepool Loop, what is unique about the app’s customizability and compatibility with other diabetes technologies, and other top points for people with diabetes and members of the diabetes care team to consider with the technology moving into the future.

A study of more than 100 adults with type 1 diabetes suggests those with increased levels of self-stigma had worse glucose control than their counterparts with lower levels of self-stigma.

Abbott's Proclaim XR spinal cord stimulation system allows patients with painful diabetic peripheral neuropathy to improve quality of life using a system that is easily incorporated into their everyday lives.

Announced on January 24, the US FDA's marketing clearance for the Tidepool Loop mobile app allows for use with compatible devices for automated insulin dosing to help manage type 1 diabetes in persons 6 years of age and older.

A prospective, dual-center study of people with high-risk type 1 diabetes using multiple daily injections aged 13-25 years demonstrates the utility of this technology in this patient population.

To celebrate the end of 2022 and the advances witnessed in the past year, our editorial team has created a list of the top 8 most popular pieces of content related to endocrinology from 2022.

To commemorate the inaugural year and the success of Diabetes Dialogue in 2022, our editorial team has compiled a list of the 5 most popular episodes from the past year. Further in this article, we offer readers a look into each of our hosts top picks for episodes during 2022.

In the December 2022 episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, sit down to discuss recent developments in the field, with a spotlight on the Dexcom G7 CGM, key takeaways from the ADA’s Standards of Care in Diabetes—2023, and perspective from the ADCES Diabetes Technology Conference 2022.

In this episode of Diabetes Dialogue, Jill Weissberg-Benchell, PhD, takes hosts through her journey to becoming a diabetes care and education specialist, the role of psychologists in the management of pediatric diabetes, and her thoughts on the evolving role of care and education specialists in the management of diabetes.

In this episode of Diabetes Dialogue, Richard Bergenstal, MD, sits down with hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, to discuss the role and evolution of technology in the management of diabetes.

An analysis of NHANES data spanning more than 3 decades provides an overview of trends in glycemic control and severe hyperglycemia among people with diabetes using insulin, including racial and ethnic disparities.

In this episode of Diabetes Dialogue, Jane Jeffrie Seley, DNP, MPH, a member of the writing committee for the ADA's Standards of Care in Diabetes—2023, joins the podcast to discuss pertinent updates in the sections of the document discussing inpatient management of diabetes within the document.

A recent survey found that most people with type 1 diabetes felt their coaches, trainers, and teachers treated them differently after learning about their diagnosis. In this column, Fran Damian, MS, RN, provides 3 simple steps to better support athletes with diabetes.

The November 2022 endocrine month in review features coverage of the FDA’s approval of teplizumab, new data related to use of GLP-1 receptor agonists, and a trio of stories on topics pertaining to diabetes technology.

A Johns Hopkins-led analysis provides a snapshot of trends in racial disparities seen in both uptake of and engagement in discussions with providers around continuous glucose monitoring and insulin pumps among adults with type 1 diabetes.

In this special edition episode of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, break down what the approval of teplizumab means for type 1 diabetes. During the episode, hosts take a deep dive into type 1 diabetes staging and hypothesize around the role of CDCES in educating primary care and other specialties to optimize the potential of teplizumab.

In this episode, our hosts are joined by Lydia Alexander, MD, president-elect of the Obesity Medicine Association, to discuss the updates in the landscape of obesity management as well as a deep dive into the recent American Gastroenterological Association guidelines for pharmacological management and the OMA's annual meeting.

In this episode of Diabetes Dialogue, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the ongoing GLP-1 RA shortage and whether or not celebrities using these agents for weight loss is a real issue in the community as well as provide insight into their top takeaways from the ADA/KDIGO consensus report.

In this special edition episode of Diabetes Dialogue, our hosts break down their top clinical takeaways from the European Association for the Study of Diabetes 2022 annual meeting, new data from the FLASH-UK trial, the global launch of Dexcom G7, and the announcement of US availability for the FreeStyle Libre 3.

In this regularly scheduled September 2022 episode of Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, provide their own perspective on DIY looping based on the results of a recent study published in the New England Journal of Medicine and also break down a new set of consensus recommendations for the use of automated insulin delivery (AID) systems in clinical practice published in Endocrine Reviews, which Isaacs helped compose as a member of the writing committee.

In this episode of Diabetes Dialogue, which was filmed just days after the conclusion of ADCES 22, our hosts take the time to dive deeper into the conference, their favorite sessions, and how the ADCES meetings have evolved to the changing role of diabetes care and education specialists over the years.

Announced on Aug. 22, the US FDA's clearance of the Omnipod 5 AID system in type 1 diabetes for patients aged 2 years and older comes less than 7 months after receiving clearance in patients aged 6 years and older.

In this article, readers will find a collection of the on-site coverage of the Association of Diabetes Care and Education Specialist (ADCES) 2022 annual meeting from Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives.

In this edition of Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives, which was filmed on-site at ADCES 22, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, sit down with Jennifer Clements, PharmD, following her sessions to discuss her work, her upcoming research interests, and ongoing trends in the field of diabetes management.

In this episode, the hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, sit down with ADCES 2022 Diabetes Care and Education Specialist of the Year Anastasia Albanese-O’Neill, PhD, to discuss her inspiration, her work within the field, and insight into the project she has decided to focus on during her year as ADCES Diabetes Care and Education Specialist of the Year.

In this special edition ADCES 22 episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, are joined by David Walton, CEO of the T1D Exchange, who takes our hosts on a deep dive into the history of the organization, what it is doing right now to improve patient care, and how it expects to grow and improve management of type 1 diabetes into the future.

In this special edition of Diabetes Dialogue recorded on-site at ADCES 22, our hosts are joined by Korey Hood, PhD, a staff psychologist and professor at Stanford University. Founder of DiabetesWise and DiabetesWisePro, Hood talks to Diana Isaacs, PharmD, and Natalie Bellini, DNP, about his efforts and how the online resources are pushing care forward.

For the July 2022 episode of Diabetes Dialogue: Therapeutics, Technology, and Real-World Perspectives, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, sit down to provide perspective on the latest advances in the fight to cure type 1 diabetes and offer insight into their experiences at the Practical Ways to Achieve Targets in Diabetes Care Conference held in Keystone, CO in mid-July.

In this episode, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss their experiences with prescribing tirzepatide (Mounjaro) and what issues patients have encountered, the prospect of new biosimilar insulins that may be coming to the market, and the misdiagnosis of type 1 diabetes in adult patients.

In the fourth and final episode from ADA 2022, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, take a deep dive into the meeting from their perspectives as a clinical pharmacy specialist and a nurse practitioner, including their picks for the most exciting advances in diabetes technology to come from the year’s largest diabetes meeting.